Background: Dementia is a heterogeneous clinical
syndrome characterized by progressive cognitive
decline that interferes with independent functioning.
Although advances in neuroimaging, fluid biomarkers, molecular diagnostics, and genetic testing have
improved etiological classification, dementia remains
fundamentally a clinical diagnosis. Biomarker findings
must therefore be interpreted within the context of the
patient’s cognitive, functional, behavioural, neurological, medical, and psychosocial presentation.
Objective: This narrative review provides a practical,
evidence-based framework for the comprehensive
clinical assessment of adults presenting with suspected dementia, with emphasis on translating contemporary diagnostic principles into routine clinical
practice across primary care, geriatrics, neurology,
psychiatry, and memory-clinic settings.
Methods: Current clinical guidelines, consensus criteria, validated assessment instruments, and contemporary evidence concerning dementia diagnosis
were narratively synthesized. The review examines
history taking and collateral information, characterization of cognitive symptom profiles, functional assessment, neurological examination, early warning
signs, longitudinal progression, behavioural and psychological symptoms, differential diagnosis, cognitive
screening, laboratory and neuroimaging evaluation,
biomarkers, and emerging digital and artificial-intelligence technologies.
Results: Accurate assessment requires integration of
multiple complementary sources of information rather than reliance on any single test. A detailed history
from both the patient and a knowledgeable informant
establishes symptom onset, tempo, affected cognitive
domains, and change from premorbid functioning.
Functional assessment is essential for distinguishing
dementia from mild cognitive impairment, while neurological and behavioural findings assist with syndrome
differentiation, severity determination, safety evaluation, and identification of reversible or contributing
conditions. Serial assessment is particularly valuable
because longitudinal changes in cognition, function,
and behaviour may be more diagnostically informative than a single evaluation. Biomarkers and artificial
intelligence can improve diagnostic confidence, subtype classification, and monitoring but should complement rather than replace clinical reasoning and
patient-centered judgment.
Conclusion: Comprehensive clinical assessment
remains the cornerstone of timely and accurate dementia diagnosis. A systematic, multidisciplinary, and
patient-centered approach integrating history, cognition, function, behaviour, neurological examination,
and appropriately selected investigations provides
the strongest basis for etiological diagnosis, individualized management, caregiver support, safety planning, and longitudinal care.
Keywords: dementia; cognitive impairment; clinical
assessment; diagnosis; functional assessment; neurological examination; neuropsychiatric symptoms;
biomarkers; artificial intelligence; patient-centered
care.
A. Abyad· World Family Medicine Journa...· 0 citations
Parkinson’s disease dementia (PDD) is a common,
disabling, and prognostically important neurocognitive syndrome arising in the context of established
Parkinson’s disease (PD). It represents one of the
major late-stage manifestations of synucleinopathy
and reflects the convergence of cortical Lewy body
pathology, cholinergic degeneration, dopaminergic
network dysfunction, Alzheimer-type co-pathology,
neuroinflammation, vascular injury, and age-related vulnerability. Clinically, PDD is characterized by
progressive impairment in attention, executive function, visuospatial processing, memory retrieval, and
behavioural regulation, typically accompanied by
neuropsychiatric symptoms such as visual hallucinations, apathy, depression, anxiety, delusions, REM
sleep behaviour disorder, and fluctuating cognition.
The diagnostic distinction between PDD and dementia with Lewy bodies remains anchored in the oneyear rule, although biological and clinicopathological
evidence increasingly supports their conceptualization as overlapping Lewy body dementias. Diagnosis
remains primarily clinical, supported by neuropsychological testing, structural and functional imaging,
exclusion of reversible contributors, and emerging
biomarkers including α-synuclein seed amplification
assays, amyloid and tau biomarkers, and neurodegeneration markers. Rivastigmine remains the bestsupported symptomatic pharmacologic therapy, while
management requires systematic rationalization of
dopaminergic and anticholinergic medication,
treatment of neuropsychiatric complications, sleep
optimization, rehabilitation, caregiver support, and
advanced-care planning. Disease-modifying
therapies remain investigational, but future directions
include biological staging, precision phenotyping,
synuclein-targeted immunotherapy, lysosomal
enhancement, neuroinflammation modulation, digital
biomarkers, and integrated trials across the Lewy
body disease spectrum.
Keywords: Parkinson’s disease dementia;
Lewy body dementia; α-synuclein;
cognitive impairment; rivastigmine;
dementia with Lewy
A. Abyad· World Family Medicine Journa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.